Selective Inhibitors of Histone Methyltransferase DOT1L: Design, Synthesis, and Crystallographic Studies

Department of Pharmacology, Baylor College of Medicine, 1 Baylor Plaza, Houston, Texas 77030, USA.
Journal of the American Chemical Society (Impact Factor: 11.44). 09/2011; 133(42):16746-9. DOI: 10.1021/ja206312b
Source: PubMed

ABSTRACT Histone H3-lysine79 (H3K79) methyltransferase DOT1L plays critical roles in normal cell differentiation as well as initiation of acute leukemia. We used structure- and mechanism-based design to discover several potent inhibitors of DOT1L with IC(50) values as low as 38 nM. These inhibitors exhibit only weak or no activities against four other representative histone lysine and arginine methyltransferases, G9a, SUV39H1, PRMT1 and CARM1. The X-ray crystal structure of a DOT1L-inhibitor complex reveals that the N6-methyl group of the inhibitor, located favorably in a predominantly hydrophobic cavity of DOT1L, provides the observed high selectivity. Structural analysis shows that it will disrupt at least one H-bond and/or have steric repulsion for other histone methyltransferases. These compounds represent novel chemical probes for biological function studies of DOT1L in health and disease.

1 Follower
  • [Show abstract] [Hide abstract]
    ABSTRACT: Within the vast landscape of histone modification lysine methylation has gained increasing attention because of its profound regulatory potential. The methylation of lysine residues on histone proteins modulates chromatin structure and thereby contributes to the regulation of DNA-based nuclear processes such as transcription, replication and repair. Protein families with opposing catalytic activities, lysine methyltransferases (KMTs) and demethylases (KDMs), dynamically control levels of histone lysine methylation and individual enzymes within these families have become candidate oncology targets in recent years. A number of high quality small molecule inhibitors of these enzymes have been identified. Several of these compounds elicit selective cancer cell killing in vitro and robust efficacy in vivo, suggesting that targeting ‘histone lysine methylation pathways’ may be a relevant, emerging cancer therapeutic strategy. Here, we discuss individual histone lysine methylation pathway targets, the properties of currently available small molecule inhibitors and their application in the context of cancer.
    Pharmacology [?] Therapeutics 01/2015; 150. DOI:10.1016/j.pharmthera.2015.01.002 · 7.75 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: DNA methylation is a mammalian epigenetic mark that is involved in defining where and when genes are expressed, both in normal cells and in the context of diseases. Like other epigenetic marks, it is reversible and can be modulated by chemical agents. Because it plays an important role in cancer by silencing certain genes, such as tumor suppressor genes, and by reactivating other regions, such as repeated elements, it is a promising therapeutic target. Two compounds are already approved to treat hematological cancers. Many efforts have been carried out to discover new molecules that are able to efficiently inhibit DNA methylation in cancer cells. We will briefly overview the foremost of these efforts by focusing on what we have learned to this point on non-nucleoside inhibitors and on what we consider to be the features of an ideal inhibitor.
    Journal of Medicinal Chemistry 11/2014; 58(6). DOI:10.1021/jm500843d · 5.48 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Modifications of the 5'-position of adenosine have been prepared via a novel 5'-carboxaldehyde synthon. The described methodology should prove useful for making related compounds in which amine-derived moieties off the 5'-position of adenosine (or related nucleoside congeners) can be easily incorporated via reductive amination, especially for the incorporation of aromatic amines.
    Nucleosides Nucleotides &amp Nucleic Acids 05/2015; 34(5):348-60. DOI:10.1080/15257770.2014.1001074 · 0.89 Impact Factor


Available from